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Abstract Cytochrome P450 (CYP) 2S1 is ‘‘orphan’’ CYP
that is overexpressed in several epithelial tissues and many
human tumors. The pure enzyme is required for better
understanding of its biological functions. Therefore, human
CYP2S1 was considered to be prepared by the gene
manipulations and heterologous expression in Escherichia
coli. Here, the conditions suitable for efficient expression
of human CYP2S1 protein from plasmid pCW containing
the human CYP2S1 gene were optimized and the enzyme
purified to homogeneity. The identity of CYP2S1 as the
product of heterologous expression was confirmed by
dodecyl sulfate–polyacrylamide gel electrophoresis, Wes-
tern blotting, and mass spectrometry. To confirm the
presence of the enzymatically active CYP2S1, the CO
spectrum of purified CYP2S1 was recorded. Since CYP2S1
was shown to catalyze oxidation of compounds having
polycyclic aromatic structures, the prepared enzyme has
been tested to metabolize the compounds having this
structural character; namely, the human carcinogen ben-
zo[a]pyrene (BaP), its 7,8-dihydrodiol derivative, and an
anticancer drug ellipticine. Reaction mixtures contained
besides the test compounds the CYP2S1 enzyme recon-
stituted with NADPH:CYP reductase (POR) in liposomes,
and/or this CYP in the presence of cumene hydroperoxide
or hydrogen peroxide. High performance liquid chro-
matography was employed for separation of BaP, BaP-7,8-
dihydrodiol, and ellipticine metabolites. The results found
in this study demonstrate that CYP2S1 in the presence of
cumene hydroperoxide or hydrogen peroxide catalyzes
oxidation of two of the test xenobiotics, a metabolite of
BaP, BaP-7,8-dihydrodiol, and ellipticine. Whereas BaP-
7,8,9,10-tetrahydrotetrol was formed as a product of BaP-
7,8-dihydrodiol oxidation, ellipticine was oxidized to
12-hydroxyellipticine, 13-hydroxyellipticine, and the
ellipticine N2-oxide.
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Introduction
Cytochrome P450 (CYP, EC 1.14.14.1) is a superfamily of
hemoproteins distributed widely throughout nature,
involved in metabolism of a broad variety of substrates and
catalyzing a variety of interesting chemical reactions [1–3].
The CYP enzymes are a component of a mixed function
oxidase (MFO) system located in the membrane of the
endoplasmic reticulum that beside the CYPs also contains
other enzymes such as NADPH:CYP oxidoreductase
(POR), and cytochrome b5 accompanied by its NADH:-
cytochrome b5 reductase [1–5].
A variety of CYP enzymes (e.g., CYP5, 8, 11, 17, 19,
21, 24, 26, and 27) are used by mammals for the synthesis
of important endogenous compounds such as steroids and
eicosanoids, besides their function in the catabolism of
natural products [1, 2]. Of the remainder of the mammalian
CYPs, a relatively small set of these enzymes accounts for
most of metabolism of drugs (i.e., human CYP1A2, 2C9,
2C19, 2D6, and 3A4). Another group of human CYPs (i.e.,
human CYP1A1, 1A2, 1B1, 2A6, 2E1, and 3A4) is
involved in the metabolism of most pro-toxicants and pro-
carcinogens that are CYP substrates [1, 3, 6, 7]. All these
data indicate that functions of most CYP enzymes are well
known. However, of 57 human CYP enzymes, 13 remain
classified as ‘‘orphans’’, because their functions are largely
unknown [8–11]. Among them, CYP2S1 was found to be
induced by the aryl hydrocarbon receptor (AHR) ligands,
by hypoxia via hypoxia-inducible factor 1 and by all-trans-
retinoic acid [12, 13]. This enzyme is expressed in
epithelial cells of tissues exposed to the environment (i.e.,
skin, respiratory, urinary, and gastrointestinal tracts), and
also in many tumors of epithelial origin [10, 12]. Inter-
estingly, CYP2S1 was described that cannot use NADPH
for oxidative metabolism of some substrates, because of its
inability to accept electrons from the NADPH/POR system
[11, 14]. However, the recent results of Guengerich with
collaborators show that in the case of CYP2S1-mediated
metabolism of 1,4-bis[[2-(dimethylamino-N-oxide)ethyl]
amino]-5,8-dihydroxyanthra-cene-9,10-dione by CYP2S1,
POR is capable of reducing this CYP [15].
Recently, we have found that a human carcinogen
benzo[a]pyrene (BaP) [16] and an anticancer drug ellip-
ticine [17–19] might be, beside classical CYPs that accept
electrons transferred from the NADPH/POR system, oxi-
dized also by other CYP enzymes, whose activities are not
dependent on POR [17, 18, 20–24]. We suggested that the
CYP2S1 enzyme, which was shown to catalyze the oxi-
dation of compounds having polycyclic aromatic structures
(such as BaP) also without participation of POR [8, 10, 11,
14], might be one of the such enzymes. Therefore, to
confirm this suggestion, the CYP2S1 efficiency to oxidize
BaP and ellipticine should be investigated in detail. How-
ever, because purification of CYP2S1 from natural
biological materials is experimentally very difficult,
heterologous expression was recently employed to obtain
the biological active CYP2S1 [9–11]. In this study, we
describe an improved method for heterologous expression
of human CYP2S1 in a prokaryotic expression system of
Escherichia coli cells as well as an efficient procedure for
its purification to homogeneity. The purified enzyme either
reconstituted with POR in liposomes or in the presence of
cumene hydroperoxide/hydrogen peroxide in vitro was
utilized to investigate its catalytic activity to oxidize car-
cinogenic BaP, its 7,8-dihydrodiol metabolite, and an
anticancer drug ellipticine.
Results and discussion
Expression of human CYP2S1 in E. coli and its
purification
When the procedure for heterologous expression of human
CYP2S1 construct in E. coli DH5a cells described by [9]
was used, the CYP2S1 production was only very low (less
than 70 nmol CYP per dm3). Moreover, even though the
co-expression of the molecular chaperon GroEL/ES that is
a suitable method to elevate the CYP2S1 expression [9]
was utilized, no dramatic increase in its expression was
found. Therefore, we examined other modifications of the
procedure to improve the CYP2S1 expression. First, the
effect of volume of the cultured growth media from 50 to
500 cm3 in different size Erlenmeyer flasks was tested. The
level of expression CYP2S1 increased up to 200 nmol CYP
per dm3 when the 100 cm3 of cultured media in 500 cm3
Erlenmeyer flask was used, compared with 50 or 500 cm3
of growth TB media in 250 cm3 and/or 2 dm3 Erlenmeyer
flasks, respectively. Second, in addition to this procedure
modification, the cell growth time was found to play a role
in the production of CYP2S1, and even in its quality. The
maximum levels of expressed CYP occurred after 24-h
cultivation, at shaking speed of 190 rpm and 29 C; higher
time of cultivation (up to 40 h) did not result to elevated
levels of CYP produced. It, moreover, led to changes in a
CYP structure, forming its degraded form, cytochrome
P420. Therefore, the 24-h cell cultivation was used in this
study and the cells prepared by this procedure were utilized
for CYP2S1 purification.
Solubilization of E. coli membranes containing CYP2S1
was achieved by 1 % 3-[(3-cholamidopropyl)dimethylam-
monio]-1-propanesulfonate hydrate (CHAPS) (w/v) present
in the solubilization buffer. The resulting supernatant was
loaded onto a column of Ni2?-nitriloacetic acid agarose
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(Ni–NTA agarose) and CYP2S1 was eluted with potassium
phosphate buffer containing 300 mmol dm-3 imidazole.
Using the sodium dodecyl sulfate–polyacrylamide gel
electrophoresis (SDS-PAGE), the purified, detergent-free
CYP2S1 (see ‘‘Experimental’’), was shown to be elec-
trophoretically homogeneous, having a molecular mass of
*50 ± 5 kDa (Fig. 1a). The CYP2S1 identity was proved
by Western blotting, using the chicken polyclonal anti-
bodies against CYP2S1 [25] (Fig. 1b) and by mass
spectrometry (Supplementary Table 1 and Supplementary
Scheme 1). The specific content of CYP2S1 was estimated
to be 4.5 nmol per mg protein, based on a bicinchoninic
acid colorimetric protein estimation method.
Spectral properties of prepared CYP2S1
The carbon monoxide (CO)-spectrum (see ‘‘Experimen-
tal’’) of prepared human CYP2S1 was recorded (Fig. 2).
This spectrum was free of cytochrome P420, indicating the
correct fold and the high quality of the prepared CYP2S1
enzyme.
Enzyme activity—oxidation of BaP, BaP-7,8-
dihydrodiol, and ellipticine by prepared CYP2S1
To evaluate enzymatic activity of purified CYP2S1, two
systems were utilized: (1) CYP2S1 reconstituted with POR
in liposomes and (2) CYP2S1 in the presence of cumene
hydroperoxide and/or hydrogen peroxide as cofactors.
Since BaP and its 7,8-dihydrodiol derivative were found as
substrates of CYP2S1 [10, 11], they were used as model
substrates of these CYP2S1 systems. In addition, because a
suggested participation of CYP2S1 in metabolism of an
anticancer drug ellipticine [17, 23, 24] has not been
examined as yet, its potency to oxidize this drug was
investigated, too. The enzyme activity of CYP2S1 to
metabolize these compounds in both systems was com-
pared with that of the CYP1A1 and/or 1B1 enzymes, for
which the test compounds are excellent substrates [3, 21,
22, 26–28].
Utilizing BaP as a compound that was described by Bui
and Hankinson [10] to be a substrate of CYP2S1, no
metabolites were detectable in both CYP2S1 systems under
the conditions used in our experiments. This finding,
namely, the result that BaP is not a substrate of CYP2S1, is
in line with the results of Guengerich and collaborators [9],
whose detected almost no CYP2S1 activity to oxidize BaP,
too. In contrast, HPLC used to analyze metabolism of one
of the BaP metabolites, BaP-7,8-dihydrodiol, with either
CYP2S1 systems showed their effectiveness to oxidize this
xenobiotic (see Supplementary Fig. 1 for CYP2S1 with
cumene hydroperoxide); BaP-7,8,9,10-tetrahydrotetrol was
identified as the reaction product (Supplementary Fig. 2).
As shown in Fig. 3, CYP1A1 or 1B1 reconstituted with
POR in liposomes oxidized BaP-7,8-dihydrodiol with up to
more than two orders of magnitude higher effectiveness
than CYP2S1 reconstituted with POR. On the contrary,
CYP2S1 in the presence of cumene hydroperoxide or
hydrogen peroxide generated up sevenfold higher levels of
Fig. 1 SDS-PAGE (a) and Western blotting (b) of heterologous
expression products in E. coli and fractions obtained during purifi-
cation of CYP2S1. Lane 1 protein Mr marker, 2 sample before
induction by IPTG, 3 production of proteins after 24 h, 4 Ni2?-
nitriloacetic acid agarose purified fraction, 5 a final concentrated
protein sample
Fig. 2 The CO-spectrum of purified human CYP2S1. Fe2?–CO vs.
Fe2? difference spectrum
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BaP-7,8,9,10-tetrahydrotetrol than CYP2S1 reconstituted
with POR. In these systems, the CYP2S1 enzyme exhibited
essentially the same (and/or even higher) effectiveness in
this reaction than analogous systems of human CYP1A1 or
1B1 (Fig. 3). Essentially no BaP-7,8-dihydrodiol metabo-
lite (BaP-7,8,9,10-tetrahydrotetrol) was detectable when
the NADPH-generating system or cumene hydroperoxide/
hydrogen peroxide cofactors were omitted from the incu-
bation mixtures (data not shown). The results found
indicate that prepared human CYP2S1 is enzymatically
active enzyme, being more effective in BaP-7,8-dihydro-
diol oxidation in the presence of cumene hydroperoxide or
hydrogen peroxide than in the system where CYP2S1 is
reconstituted with POR. They also demonstrate that by its
potency to oxidize BaP-7,8-dihydrodiol, this CYP can
increase the overall metabolism of BaP catalyzed by other
CYPs, including CYP1A1 and 1B1, the most important
CYPs oxidizing this carcinogen [20, 29].
In the case of ellipticine, only the systems of CYP2S1
containing cumene hydroperoxide and/or hydrogen perox-
ide were capable of oxidizing this drug (Figs. 4, 5),
whereas this CYP reconstituted with POR in liposomes in
the presence of NADPH-generating system was without
such activity (data not shown). Cumene hydroperoxide was
an up to one order of magnitude more effective cofactor for
ellipticine oxidation than hydrogen peroxide (Fig. 5a). Of
the ellipticine metabolites, 12-hydroxyellipticine and
13-hydroxyellipticine were the major metabolites formed
by this CYP2S1 system, while 9-hydroxyellipticine and the
ellipticine N2-oxide were the minor ones (Fig. 5a). Negli-
gible amounts of these ellipticine metabolites were
generated by CYP2S1 without cofactors (data not
shown). The formation of 12-hydroxyellipticine and
13-hydroxyellipticine is the pharmacologically important
feature, because these metabolites generate two major
deoxyguanosine adducts in DNA [17–19, 30, 31, 32] that
are responsible for ellipticine anticancer activity [17–19,
33, 34]. The levels of activation metabolites were increased
with increasing concentrations of CYP2S1 with cumene
hydroperoxide, while essentially no such effects were
found when hydrogen peroxide was used as a cofactor
(Fig. 5a). The only low amounts of the ellipticine
metabolites were generated by the system of human
CYP1A1 in the presence of both peroxides, 12-hydrox-
yellipticine was even not produced by this CYP at all
(Fig. 5b). The system of human CYP1A1 reconstituted
with POR in liposomes was not examined in this work,
because its efficiency to oxidize this drug was investigated
previously in detail; 9-hydroxyellipticine, 7-hydroxyellip-
ticine, and 13-hydroxyellipticine were formed as the major
metabolites in this CYP1A1 system, while the ellipticine
N2-oxide as a minor product and 12-hydroxyellipticine was
not a product of ellipticine oxidation by this enzyme [19,
31, 32]. A pattern of the metabolites formed by this
CYP1A1 system is hence quite different from that gener-
ated by this enzyme in the presence of either test peroxides
(Fig. 5b). The results found demonstrate the effectiveness
of CYP2S1 in ellipticine oxidation and confirmed the
suggestion of its participation in ellipticine metabolism
catalyzed by CYP without POR [17, 23, 24]. Because of
the high expression of CYP2S1 in many tumor cells, the
results also emphasized its role in metabolism of ellipticine
in cancer tissues that was found previously [17, 19, 33, 34].
Conclusion
Since functions of many ‘‘orphan’’ CYPs are largely
unknown [8–11], their investigation is a challenge for
research of many laboratories. Therefore, in this study we
examined a function of ‘‘orphan’’ CYP2S1, the enzyme
which is able to metabolize several substrates via the
NADPH/POR-independent activity [9–11]. For such a
study, we prepared enzymatically active human recombi-
nant CYP2S1 and further utilized to evaluate its potency to
oxidize one of the anticancer drugs, ellipticine. This anti-
tumor agent was chosen, because it was found that it can be
metabolized also by the CYP enzymes that do not need the
NADPH/POR system, and we suggested that CYP2S1
might be one of these CYPs [17, 23, 24]. Our data
demonstrate that CYP2S1 is indeed capable of oxidizing
ellipticine, in the systems containing the peroxide cofac-
tors, therefore, via the NADPH/POR-independent activity.
CYP2S1 in the presence of cumene hydroperoxide oxidizes
ellipticine predominantly to its activation metabo-
lites, 12-hydroxyellipticine and 13-hydroxyellipticine, the
CONTROL CYP2S1 CYP1A1 CYP1B1
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Fig. 3 Formation of BaP-7,8,9,10-tetrahydrotetrol by human
CYP2S1 in different systems. Human CYP1A1 or CYP1B1 known
to oxidize BaP- 7,8-dihydrodiol to BaP-7,8,9,10-tetrahydrotetrol were
used as positive controls. Data shown are averages and standard
deviation from three parallel measurements
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metabolites responsible for its pharmacological efficiencies
that result from formation of covalent ellipticine-derived
DNA adducts. These adducts were found to be generated in
rat lung and kidney in vivo, indeed even without partici-
pation of the NADPH/POR system [17, 18, 23, 24].
Because CYP2S1 can be expressed in several tumor
cells sensitive to ellipticine [10, 25, 32–36], the data found
in this work suggest that this CYP can contribute to the
ellipticine antitumor activity in these cells. This suggestion
need, however, to be explored by further studies. Utiliza-
tion of the tumor cells highly expressing CYP2S1 [10, 25]
is planned to be utilized for such studies.
Experimental
Ellipticine and BaP were from Sigma Chemical Co (St Louis,
MO, USA). These and other chemicals used in the experi-
ments were of analytical purity or better. (±)-Trans-7,8-
dihydroxy-7,8-dihydrobenzo[a]pyrene (BaP-7,8-dihydro-
diol) was prepared at the Biochemical Institute for
Environmental Carcinogenesis, Germany, as described [37].
Escherichia coli DH5a cells with the CYP2S1 gene were
a gift of Professor F.P. Guengerich (Vanderbilt University
School of Medicine, Nashville, Tennessee, USA). It should
be noted that optimization of the conditions suitable for
production of plasmid pCW containing the CYP2S1 gene,
was carried out in his laboratory and further used for
expression of CYP2S1 [9]. It was necessary to modify the
C-terminal end of the CYP2S1 cDNA by Histidyl-5-Tag
and the N-terminal end before the well-conserved proline-
rich region (see [9] for detail).
Human CYP1A1, 1B1 and POR were prepared by
heterologous expression in E. coli in our laboratory
(Department of Biochemistry, Faculty of Sciences, Charles
University, Prague, Czech Republic), by J. Milichovsky´,
essentially in the same manner as described previously
[38–40].
Expression of human CYP2S1 in E. coli
Escherichia coli cultivation was carried out essentially as
described previously [9, 41–43]. A single bacterial colony
Fig. 4 HPLC analysis of ellipticine metabolites formed by human recombinant CYP2S1 in the presence of cumene hydroperoxide
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was picked, and the bacteria were grown overnight in
15 cm3 of a Luria Broth (LB) liquid medium (Sigma
Chemical Co, St Louis, MO, USA) containing
100 mg cm-3 ampicillin, and 50 mg cm-3 kanamycin at
37 C with shaking at 200 rpm. The overnight culture was
inoculated 1:100 into 100 cm3 of a Terrific Broth (TB)
medium (Sigma Chemical Co, St Louis, MO, USA) con-
taining 100 mg cm-3 ampicilin, 50 mg cm-3 kanamycin,
and 0.025 % (v/v) of a mixture of trace elements (27 g
FeCl36H2O, 2.0 g ZnCl24H2O, 2.0 g CaCl26H2O, 2.0 g
Na2MoO4, 1.0 g CaCl22H2O, 1.0 g CuCl2, 0.5 g H3BO3,
and 100 cm3 concentrated HCl per 1 dm3 of distilled
water) in a 500 cm3 flask. Sixteen flasks of cultures were
incubated for *4 h at 37 C with shaking at 220 rpm until
they attained an OD600 of 0.5–0.7, then were supplemented
with 1 mmol dm-3 isopropyl b-D-1-thiogalactopyranoside
(IPTG) medium (Sigma Chemical Co, St Louis, MO,
USA), 1 mg cm-3 arabinose, and 0.5 mmol dm-3 a heme
precursor, d-aminolevulinic acid (d-ALA) (Sigma Chemi-
cal Co, St Louis, MO, USA), and cultured for 24 h at 29 C
with shaking at 190 rpm. Induction of GroEL/ES and
CYP2S1 synthesis was achieved in the presence of arabi-
nose and IPTG, respectively. The expression level of
CYP2S1 was monitored at 12 and 24 h.
Escherichia coli membranes were prepared as descri-
bed previously [44]. All steps were done at 4 C. The
cells were harvested by centrifugation at 5000g for
20 min. Pellets were resuspended in 1:20 vol of
Tris/sucrose/ethylenediaminetetraacetic acid (EDTA)
(TSE) buffer (10 mmol dm-3 Tris–acetate, pH 7.4,
500 mmol dm-3 sucrose, 0.5 mmol dm-3 EDTA).
Lysozyme was added to a concentration of 0.2 mg cm-3,
and the suspensions were diluted twofold with distilled
H2O before incubation on ice for 30 min. The resulting
spheroplasts were sedimented at 4000 g at 4 C for
20 min, and resuspended in 100 mmol dm-3 potassium
phosphate buffer, pH 7.4, containing 6 mmol dm-3
magnesium acetate, 20 % glycerol (v/v), and
10 mmol dm-3 b-mercaptoethanol (ME). The protease
inhibitors, phenylmethylsulfonyl fluoride (PMSF), apro-
tinin, leupeptin, and bestatin (all Sigma Chemical Co, St
Louis, MO, USA) were added to a final concentration of
1 mmol dm-3, 1 lg cm-3, 2, and 1 lmol dm-3, respec-
tively. Suspensions of spheroplasts were sonicated ten
times for 30 s each, on ice, and centrifuged at 10,000g at
4 C for 20 min. Supernatants were centrifuged at
108,000g at 4 C for 65 min. Sedimented membrane
fractions were resuspended in 100 mmol dm-3 potassium
phosphate buffer, pH 7.4, containing 6 mmol dm-3
magnesium acetate, 20 % glycerol (v/v), and
10 mmol dm-3 ME. The membrane preparation was
stored at -70 C until use. The reddish pellets represent
the CYP containing membrane fraction.
Purification of recombinant human CYP2S1
Membrane fractions of E. coli were diluted up to
2 mg cm-3 of protein concentration with 100 mmol dm-3
potassium phosphate buffer, pH 7.4, containing 20 %
glycerol (v/v), 0.5 mol dm-3 NaCl, 10 mmol dm-3 ME
(solubilization buffer) and solubilized with 1.0 % CHAPS
(Sigma Chemical Co, St Louis, MO, USA) (w/v). The
detergent was dissolved in solubilization buffer. After
stirring for 3 h at 4 C, the resulting solutions were cen-
trifuged at 108,000g at 4 C for 65 min to eliminate
insoluble materials. The supernatants were then applied on
a column of Ni–NTA agarose (QIAGEN) (Hilden, Ger-
many) equilibrated with the solubilization buffer [9]. After
washing of the column with 10 volumes of
100 mmol dm-3 potassium phosphate buffer, pH 7.4,
containing 20 % glycerol (v/v), 0.5 mol dm-3 NaCl, 0.5 %
CHAPS (w/v) and 10 mmol dm-3 imidazole, the CYP2S1
enzyme was eluted with 100 mmol dm-3 potassium
phosphate buffer, pH 7.4, containing 20 % glycerol (v/v),
0.5 mol dm-3 NaCl, 0.5 % CHAPS (w/v) and
300 mmol dm-3 imidazole. The CHAPS was removed by
extensive dialysis against 200-fold volume of
100 mmol dm-3 potassium phosphate buffer, pH 7.4 con-
taining 20 % glycerol (v/v), 0.1 mmol dm-3 EDTA, and
0.1 mmol dm-3 dithiothreitol (DTT) (dialysis buffer). In
the last step of dialysis, the dialysis buffer without DTT
was used. The final fraction of CYP2S1 was concentrated
by ultrafiltration using an YM-30 membrane (Millipore).
SDS-PAGE was used to assess the final protein purity.
Determination of CYP and protein contents
As found by Omura and Sato [45], when CYP is in the
reduced state and complexed with CO, it exhibits the
classic CO difference spectrum with a maximum at
450 nm. This spectral property is employed for the specific
estimation of CYP content and for evaluation whether the
purified enzyme exists in a correctly folded protein state.
Therefore, the concentration of CYP was estimated by this
method, described by Omura and Sato [45] that is based on
the absorption of the complex of reduced CYP with CO.
The CYP2S1 content was calculated using an extinction
coefficient of 91 [mmol dm-3]-1 cm-1. Protein concen-
trations were estimated using a bicinchonic acid assay
(BCA, ThermoFisher Scientific, USA) with bovine serum
albumin as a standard [46].
Determination of CYP2S1 protein levels by Western
blotting
Samples containing subcellular fractions from bacteria or
the purified protein were subjected to electrophoresis on
I. Mrı´zova´ et al.
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the 10 % polyacrylamide gel and transferred onto a
polyvinylidene fluoride (PVDF) membrane as reported [22,
47]. The membranes were then exposed overnight at 4 C
to the chicken polyclonal antibodies against CYP2S1 pre-
pared as described previously [25] and the antigen–
antibody complex was visualized with an alkaline phos-
phatase-conjugated goat anti-rabbit IgG antibody (1:1428,
Sigma-Aldrich, USA) and 5-bromo-4-chloro-3-indolyl-
phosphate/nitrobluetetrazolium as chromogenic substrate
[48].
Measurement of CYP2S1 enzyme activities
Enzymatic activity of purified CYP2S1 was analyzed using
two systems: (1) CYP2S1 reconstituted with POR in lipo-
somes and (2) CYP2S1 in the presence of cumene
hydroperoxide and/or hydrogen peroxide.
Incubation mixtures containing purified CYP reconsti-
tuted with human POR contained CYP2S1 (or CYP1A1 or
1B1) and POR. Briefly, CYP was reconstituted as follows
(200 pmol CYP with 200 pmol POR, 0.1 mmol cm-3
liposomes [dilauroyl phosphatidylcholine, dioleyl phos-
phatidylcholine, dilauroyl phosphatidylserine (1:1:1)
(Sigma Chemical Co, St Louis, MO, USA)], 3 mmol dm-3
reduced glutathione, and 50 mmol dm-3 HEPES/KOH
buffer, pH 7.4) [49]. An aliquot of this mixture was then
added to incubation mixtures.
Incubation mixtures used to study metabolism of BaP,
BaP-7,8-dihydrodiol, or ellipticine contained
100 mmol dm-3 sodium phosphate buffer (pH 7.4),
NADPH-generating system (1 mmol dm-3 NADP?,
10 mmol dm-3 D-glucose-6-phosphate, 1 U per cm-3 D-
glucose-6-phosphate dehydrogenase, Sigma Chemical Co,
St Louis, MO, USA), 0.05 cm3 CYP reconstituted system,
10 lmol dm-3 BaP or 133 lmol dm-3 BaP-7,8-dihydro-
diol or 10 lmol dm-3 ellipticine (dissolved in 0.005 cm3
DMSO) in a final volume of 0.5 cm3. The reaction was
initiated by adding 0.05 cm3 of the NADPH-generating
system. Control incubations were carried out either without
CYP enzyme or without the NADPH-generating system or
without the substrate. After incubation in open tubes
(37 C, 20 min), 0.005 cm3 of 1 mmol dm-3 phenacetin in
methanol was added as an internal standard. The reactions
catalyzed oxidation of BaP or BaP-7,8-dihydrodiol and
ellipticine by human CYP1A1 was linear up to 60 and
30 min, respectively [26, 28, 49]. Metabolites were
extracted twice with ethyl acetate (2 9 1 cm3) and evap-
orated to dryness. The samples were dissolved in
0.025 cm3 methanol and metabolites of the tested sub-
strates formed in these systems separated by HPLC.
Metabolites of BaP and BaP-7,8-dihydrodiol were sepa-
rated by HPLC and identities of their structures were
carried out as described [28, 49, 50]. HPLC analysis of
ellipticine metabolites and identities of their structures
were performed as described previously [26, 31, 32].
Incubation mixtures used to study metabolism of BaP,
BaP-7,8-dihydrodiol, or ellipticine in the presence of
cumene hydroperoxide or hydrogen peroxide contained
100 mmol dm-3 sodium phosphate buffer (pH 7.4),
0.1–0.5 lmol dm-3 CYP, 10 lmol dm-3 BaP or
133 lmol dm-3 BaP-7,8-dihydrodiol or 10 lmol dm-3
ellipticine (dissolved in 0.005 cm3 DMSO) in a final vol-
ume of 500 cm3. The reaction was initiated by adding
cumene hydroperoxide or hydrogen peroxide to their final
concentrations of 1 mmol dm-3. Control incubations were
carried out either without CYP or without peroxides or
without substrates. After incubation in open tubes (37 C,
10 min), 0.005 cm3 of 1 mmol dm-3 phenacetin in
methanol was added as an internal standard. Metabolites
were extracted twice with ethyl acetate (2 9 1 cm3) and
evaporated to dryness. The samples were dissolved in
0.025 cm3 methanol and different metabolites formed in
these systems were separated by HPLC. Metabolites of
BaP, BaP-7,8-dihydrodiol and ellipticine were separated by
HPLC and their structure indentified as described above.
The peak areas of BaP, BaP-7,8-dihydrodiol, and ellipticine
were calculated relative to the peak area of the internal
standard (phenacetin), and expressed as relative peak areas.
Mass spectrometry of purified CYP2S1
The identity and integrity of recombinant protein of human
CYP2S1 was verified by MALDI-TOF/TOF (Ultra-FLEX
III mass spectrometer, Bruker-Daltonics, Bremen, Ger-
many) mass spectrometer using a-cyano-4-
hydroxycinnamic acid as a matrix. The protein band from
SDS-PAGE was destained, cysteine residues were modified
by iodoacetamide, and protein was digested by trypsin
endoprotease (Promega Corp., Madison, USA). The
resulting peptide mixture was extracted and the MS and
MS/MS spectra of corresponding m/z signals for peptide
identity verification were acquired and manually inter-
preted (54 % of protein sequence coverage) [51].
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